288 related articles for article (PubMed ID: 35093634)
1. Generating 3D human cardiac constructs from pluripotent stem cells.
Liu C; Feng X; Li G; Gokulnath P; Xiao J
EBioMedicine; 2022 Feb; 76():103813. PubMed ID: 35093634
[TBL] [Abstract][Full Text] [Related]
2. From engineered heart tissue to cardiac organoid.
Cho J; Lee H; Rah W; Chang HJ; Yoon YS
Theranostics; 2022; 12(6):2758-2772. PubMed ID: 35401829
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional cardiac models: a pre-clinical testing platform.
Groen E; Mummery CL; Yiangou L; Davis RP
Biochem Soc Trans; 2024 Jun; 52(3):1045-1059. PubMed ID: 38778769
[TBL] [Abstract][Full Text] [Related]
4. A Universal and Robust Integrated Platform for the Scalable Production of Human Cardiomyocytes From Pluripotent Stem Cells.
Fonoudi H; Ansari H; Abbasalizadeh S; Larijani MR; Kiani S; Hashemizadeh S; Zarchi AS; Bosman A; Blue GM; Pahlavan S; Perry M; Orr Y; Mayorchak Y; Vandenberg J; Talkhabi M; Winlaw DS; Harvey RP; Aghdami N; Baharvand H
Stem Cells Transl Med; 2015 Dec; 4(12):1482-94. PubMed ID: 26511653
[TBL] [Abstract][Full Text] [Related]
5. Current Strategies and Challenges for Purification of Cardiomyocytes Derived from Human Pluripotent Stem Cells.
Ban K; Bae S; Yoon YS
Theranostics; 2017; 7(7):2067-2077. PubMed ID: 28638487
[TBL] [Abstract][Full Text] [Related]
6. 3D Microwell Platform for Cardiomyocyte Differentiation of Human Pluripotent Stem Cells.
Branco MA; Dias TP; Cotovio JP; Rodrigues CAV; Fernandes TG; Cabral JMS; Diogo MM
Methods Mol Biol; 2022; 2454():127-143. PubMed ID: 33145715
[TBL] [Abstract][Full Text] [Related]
7. Oxygen Is an Ambivalent Factor for the Differentiation of Human Pluripotent Stem Cells in Cardiac 2D Monolayer and 3D Cardiac Spheroids.
Souidi M; Sleiman Y; Acimovic I; Pribyl J; Charrabi A; Baecker V; Scheuermann V; Pesl M; Jelinkova S; Skladal P; Dvorak P; Lacampagne A; Rotrekl V; Meli AC
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440843
[TBL] [Abstract][Full Text] [Related]
8. Application of human pluripotent stem cells and pluripotent stem cell-derived cellular models for assessing drug toxicity.
Apáti Á; Varga N; Berecz T; Erdei Z; Homolya L; Sarkadi B
Expert Opin Drug Metab Toxicol; 2019 Jan; 15(1):61-75. PubMed ID: 30526128
[No Abstract] [Full Text] [Related]
9. A Change of Heart: Human Cardiac Tissue Engineering as a Platform for Drug Development.
Bremner SB; Gaffney KS; Sniadecki NJ; Mack DL
Curr Cardiol Rep; 2022 May; 24(5):473-486. PubMed ID: 35247166
[TBL] [Abstract][Full Text] [Related]
10. Maturing differentiated human pluripotent stem cells in vitro: methods and challenges.
Ottaviani D; Ter Huurne M; Elliott DA; Bellin M; Mummery CL
Development; 2023 Jun; 150(11):. PubMed ID: 37260361
[TBL] [Abstract][Full Text] [Related]
11. Lessons from the heart: mirroring electrophysiological characteristics during cardiac development to in vitro differentiation of stem cell derived cardiomyocytes.
van den Heuvel NH; van Veen TA; Lim B; Jonsson MK
J Mol Cell Cardiol; 2014 Feb; 67():12-25. PubMed ID: 24370890
[TBL] [Abstract][Full Text] [Related]
12. Development of a novel two-dimensional directed differentiation system for generation of cardiomyocytes from human pluripotent stem cells.
Moon SH; Ban K; Kim C; Kim SS; Byun J; Song MK; Park IH; Yu SP; Yoon YS
Int J Cardiol; 2013 Sep; 168(1):41-52. PubMed ID: 23044428
[TBL] [Abstract][Full Text] [Related]
13. Systems for the Functional Evaluation of Human Heart Tissues Derived from Pluripotent Stem Cells.
Murata K; Masumoto H
Stem Cells; 2022 Jun; 40(6):537-545. PubMed ID: 35303744
[TBL] [Abstract][Full Text] [Related]
14. Epicardially secreted fibronectin drives cardiomyocyte maturation in 3D-engineered heart tissues.
Ong LP; Bargehr J; Knight-Schrijver VR; Lee J; Colzani M; Bayraktar S; Bernard WG; Marchiano S; Bertero A; Murry CE; Gambardella L; Sinha S
Stem Cell Reports; 2023 Apr; 18(4):936-951. PubMed ID: 37001515
[TBL] [Abstract][Full Text] [Related]
15. Correlation between frataxin expression and contractility revealed by in vitro Friedreich's ataxia cardiac tissue models engineered from human pluripotent stem cells.
Wong AO; Wong G; Shen M; Chow MZ; Tse WW; Gurung B; Mak SY; Lieu DK; Costa KD; Chan CW; Martelli A; Nabhan JF; Li RA
Stem Cell Res Ther; 2019 Jul; 10(1):203. PubMed ID: 31286988
[TBL] [Abstract][Full Text] [Related]
16. Advances in Manufacturing Cardiomyocytes from Human Pluripotent Stem Cells.
Floy ME; Shabnam F; Simmons AD; Bhute VJ; Jin G; Friedrich WA; Steinberg AB; Palecek SP
Annu Rev Chem Biomol Eng; 2022 Jun; 13():255-278. PubMed ID: 35320695
[TBL] [Abstract][Full Text] [Related]
17. Biowire platform for maturation of human pluripotent stem cell-derived cardiomyocytes.
Sun X; Nunes SS
Methods; 2016 May; 101():21-6. PubMed ID: 26546730
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening.
Dick E; Rajamohan D; Ronksley J; Denning C
Biochem Soc Trans; 2010 Aug; 38(4):1037-45. PubMed ID: 20659000
[TBL] [Abstract][Full Text] [Related]
19. Modeling endodermal organ development and diseases using human pluripotent stem cell-derived organoids.
Pan FC; Evans T; Chen S
J Mol Cell Biol; 2020 Aug; 12(8):580-592. PubMed ID: 32652003
[TBL] [Abstract][Full Text] [Related]
20. Universal cardiac induction of human pluripotent stem cells in two and three-dimensional formats: implications for in vitro maturation.
Zhang M; Schulte JS; Heinick A; Piccini I; Rao J; Quaranta R; Zeuschner D; Malan D; Kim KP; Röpke A; Sasse P; Araúzo-Bravo M; Seebohm G; Schöler H; Fabritz L; Kirchhof P; Müller FU; Greber B
Stem Cells; 2015 May; 33(5):1456-69. PubMed ID: 25639979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
